SCHEMBL7989737

SCHEMBL7989737

C[C@H]1OCN[C@@H]1C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7993099 1.00
SCHEMBL19064720 1.00
SCHEMBL13502443 0.87 SLC1A2 (0.33)
SCHEMBL17740136 0.78 SLC1A2 (0.47)
SCHEMBL15571615 0.78 SLC1A2 (0.47)
SCHEMBL17740138 0.78 SLC1A2 (0.47)
SCHEMBL2071540 0.78 SLC1A2 (0.47)
SCHEMBL2032498 0.78 SLC1A2 (0.47)
SCHEMBL978535 0.78 SLC1A2 (0.47)
SCHEMBL17428705 0.77 CHRNB2 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117603152-A Novel chiral binuclear rhodium complex and preparation method and application thereof 肇庆学院 2024-02-27 CN disclosed
US-11149002-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2021-10-19 US disclosed
US-20210078947-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-03-18 US disclosed
EP-3166939-B1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2019-06-05 EP disclosed
US-20190031607-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-01-31 US disclosed
US-10125098-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2018-11-13 US disclosed
US-20180265465-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-09-20 US disclosed
US-10005724-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2018-06-26 US disclosed
US-20170190662-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-07-06 US disclosed
EP-3166939-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF Genentech, Inc. (US) 2017-05-17 EP disclosed
US-9242954-B2 Lactol and acetal intermediates for making prostaglandins UNIVERSITY OF BRISTOL (GB) 2016-01-26 US disclosed
WO-2016007534-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-01-14 WO disclosed
US-20150158837-A1 Compound And Method TOPOKINE THERAPEUTICS, INC. 2015-06-11 US disclosed
US-20150148524-A1 AMINO ACID ANALOGUES AND METHODS FOR THEIR SYNTHESIS UNIV MONASH (AU) 2015-05-28 US disclosed
US-8748570-B2 Insulin analogues SYNGENE LIMITED (AU) 2014-06-10 US disclosed
WO-2013186550-A1 COMPOUND AND METHOD UNIVERSITY OF BRISTOL (GB) 2013-12-19 WO disclosed
US-20120225811-A1 INSULIN ANALOGUES POLYCHIP PHARMACEUTICALS PTY LTD (AU) 2012-09-06 US disclosed
US-6291432-B1 (R)-N-(2-METHYLBENZYL)-3-((2S, 3S)-3-(N-(2-CHROMONECARBONYL)-L-ASPARAGINYL)AMINO-2-HYDROXY-4-PHENYLBUTANO YL)-5,5-DIMETHYL-1,3-THIAZOLIDINE-4-CARBOXAMIDE CAN BE GIVEN AS A TYPICAL EXAMPLE OF THIS COMPOUND. JAPAN ENERGY CORPORATION (JP) 2001-09-18 US disclosed
EP-0900566-A1 NOVEL TRIPEPTIDE COMPOUNDS AND ANTI-AIDS DRUGS JAPAN ENERGY CORPORATION (JP) 1999-03-10 EP disclosed
US-4321392-A Mercaptoacyl derivatives of 4-oxazolidine-carboxylic acids E. R. SQUIBB & SONS, INC. (US) 1982-03-23 US disclosed